Research from a () and King’s College London collaboration suggest that the cannabinoids CBD and CBG in combination have significant anti-inflammatory activity in the lung.
The partnership released the paper investigating the anti-inflammatory effects of two of the non-psychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG) alone and in combination, in a model of pulmonary inflammation.
Chief executive Marc Howells is very excited about the results and is keen to develop the research further. “It could be the turning point and revolutionary for how people can see, use and reap the benefits that we believe are present in CBD.”
He adds the share price is not reflecting the potential of the company which has “the manufacturing capability all the way to the shelf capability.”